SAR-AD-203  ·  Sarika Bio
Site Feasibility & Evaluation Questionnaire — Risankizumab added to lebrikizumab in atopic dermatitis · Protocol v0.4 · Phase 2a

Site Feasibility Questionnaire

Access to this questionnaire is by personal invitation link only. If you were invited to complete it, please use the link in your invitation email. If you have lost your link, contact the sponsor team.